AQST
Aquestive Therapeutics, Inc.
Overview
Aquestive Therapeutics, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $637.3M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 10, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-1413 Q&A exchanges
- Q4 FY2025Earnings2026-03-0517 Q&A exchanges
- Q3 FY2025Earnings2025-11-0614 Q&A exchanges
- Q2 FY2025Earnings2025-08-1211 Q&A exchanges
- Q1 FY2025Earnings2025-05-1320 Q&A exchanges
- Q4 FY2024Earnings2025-03-0624 Q&A exchanges
- Q3 FY2024Earnings2024-11-0530 Q&A exchanges
- Q2 FY2024Earnings2024-08-0720 Q&A exchanges
- Q1 FY2024Earnings2024-05-0817 Q&A exchanges
- Q4 FY2023Earnings2024-03-0620 Q&A exchanges
- Q3 FY2023Earnings2023-11-0719 Q&A exchanges
- Q2 FY2023Earnings2023-08-0813 Q&A exchanges
- Q1 FY2023Earnings2023-05-0315 Q&A exchanges
- Q4 FY2022Earnings2023-03-0824 Q&A exchanges
- Q3 FY2022Earnings2022-11-0219 Q&A exchanges
- Q2 FY2022Earnings2022-08-0314 Q&A exchanges
- Q1 FY2022Earnings2022-05-0416 Q&A exchanges
- Q4 FY2021Earnings2022-03-0912 Q&A exchanges
- Q3 FY2021Earnings2021-11-0314 Q&A exchanges
- Q2 FY2021Earnings2021-08-0416 Q&A exchanges
- Q1 FY2021Earnings2021-05-0523 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-10EPS— vs $-0.12—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-10 | — | $-0.12 | — | — | — | — | EODHD |
Source: EODHD. AQST reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks AQST's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 100% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 7 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.75 | $0.73 | +3.1% | +1.6% | +2.9% |
| Q4 FY2026 | $0.73 | $0.69 | +5.6% | +6.5% | +4.7% |
| Q3 FY2026 | $0.84 | $0.78 | +7.8% | +7.2% | +5.3% |
| Q2 FY2026 | $0.78 | $0.67 | +16.7% | +2.4% | +3.6% |
| Q1 FY2025 | $1.10 | $0.95 | +16.0% | +3.2% | +1.5% |
| Q4 FY2025 | $0.84 | $0.76 | +10.4% | +9.5% | +9.5% |
| Q3 FY2025 | $0.80 | $0.75 | +7.0% | +0.2% | -2.6% |
| Q2 FY2025 | $1.06 | $0.92 | +15.0% | +2.5% | +0.8% |
| Q1 FY2024 | $0.83 | $0.77 | +7.5% | +4.1% | +6.5% |
| Q4 FY2024 | $1.15 | $1.02 | +13.0% | +2.5% | -0.2% |
Guidance change history
Sample- Q1 FY2026Maintained2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Daniel BarberCEO1 yr 3 mo21 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
- A Ernest Toth JrCFO3 mo1 callCurrentSample
CFO since 2026 • 2/2 beats (100%) • last guidance cut Q2 FY2026
- Cassie JungCOO1 yr 3 mono recorded callsCurrentSample
COO since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
- Thomas A ZalewskiChief Legal Officer2 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance cut Q2 FY2026
- Lori J BraenderChief Legal Officer3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance raise Q2 FY2026
- Matthew J GreenhawtChief Medical Officer3 mo2 callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • last call held guidance Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AQST.
$ curl https://api.spokenalpha.com/v1/companies/AQSTFAQ
Frequently asked about AQST
Where can I find Aquestive Therapeutics, Inc.'s (AQST) earnings call transcripts?
Spoken Alpha indexes AQST's earnings call transcripts at https://spokenalpha.com/companies/AQST. Each call links to attributed speakers and parsed analyst Q&A. Aquestive Therapeutics, Inc.'s own investor relations page is at https://investors.aquestive.com/investor-relations.
When was Aquestive Therapeutics, Inc.'s most recent earnings call?
Aquestive Therapeutics, Inc. (AQST) held its most recent earnings call on 2026-05-14, covering fiscal Q1 2026.
What sector is AQST in?
Aquestive Therapeutics, Inc. (AQST) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).